DiabInnov


DiabInnov is a research platform focused on innovative strategies for the treatment of metabolic disorders and their comorbidities, aiming to provide significant advances in patient care. It promotes dialogue between pharmaceutical companies, medical device manufacturers, scientists, researchers, and surgeons to facilitate patents, CE marking, surgical approaches, and expertise in biotechnological innovation.

Industries

biotechnology
consumer-research
medical-device

Nr. of Employees

medium (51-250)

DiabInnov

INSERM 1190, 1 place de Verdun, Faculté de Médecine, Pôle Recherche – 59045 Lille, France


Products

ABOS Biobank (annotated metabolic tissue and blood collection)

A collection of metabolic tissues and blood samples from a clinical cohort (severely obese patients) with associated clinical annotation to support biomarker discovery and translational studies (clinical trial NCT01129297).

Dynamic perifusion functional assay

In vitro perifusion platform and protocols for dynamic assessment of insulin and hormone secretion from islets to evaluate drug effects, stimuli responses and device performance in vitro.

Translational large animal testing platform

Surgical and preclinical infrastructure for implantation and testing of metabolic medical devices using minipig/pig models and operating-room conditions.


Services

Functional, molecular and imaging analyses of human pancreatic islets including dynamic hormone secretion assays, gene and protein expression, histology, siRNA studies and in vivo graft evaluation.

Discovery and validation of molecular biomarkers using annotated clinical cohorts and tissue collections, supported by analytic assays and cohort data.

Support for device design and development including early-state analysis, prototype validation, in vivo proof-of-concept, verification and surgical usability testing in large animal models and operating-room environments.

Expertise Areas

  • Human islet biology and transplantation
  • Preclinical metabolic disease models (rodent and large animal)
  • Medical device preclinical development and validation
  • Biomarker discovery and validation from clinical cohorts
  • Show More (3)

Key Technologies

  • Dynamic perifusion assays
  • qPCR and digital PCR
  • Western blot
  • Immunofluorescence and confocal microscopy
  • Show More (7)

News & Updates

Our new paper classifying type 2 diabetes into three subgroups was recently published in The Lancet Diabetes & Endocrinology journal.

A major first for our biotherapy team in conjunction with the transplant team at the Lille University Hospital.

The “Victor and Erminia Mescle 2021 Prize” of the Fondation pour la recherche médicale (FRM) has been awarded to Professor François Pattou for his research.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.